Expand VTRS Menu
VTRS MENU

VTRS Latest Press Releases

-- July 1, 2026 --

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 PRNewswire 6:59 AM

-- June 29, 2026 --

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy PRNewswire 6:59 AM

-- June 16, 2026 --

Viatris Recognized as One of the 2026 Best Workplaces in Canada PRNewswire 6:59 AM

-- May 18, 2026 --

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain PRNewswire 8:00 AM

-- May 7, 2026 --

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference PRNewswire 4:30 PM
Viatris Reports First-Quarter 2026 Financial Results PRNewswire 6:59 AM

-- May 5, 2026 --

Viatris Announces Quarterly Dividend PRNewswire 6:59 AM

-- May 4, 2026 --

Viatris Announces Chief Financial Officer Transition PRNewswire 4:30 PM

-- May 1, 2026 --

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting PRNewswire 6:59 AM

-- April 13, 2026 --

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 PRNewswire 6:59 AM

-- April 10, 2026 --

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting PRNewswire 6:59 AM

-- March 23, 2026 --

Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) PRNewswire 6:59 AM

-- March 19, 2026 --

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 PRNewswire 8:30 AM

-- February 26, 2026 --

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results PRNewswire 6:59 AM
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend PRNewswire 6:55 AM

-- February 25, 2026 --

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia PRNewswire 6:59 AM

-- February 19, 2026 --

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026 Globe Newswire 9:02 AM
Market Data Delayed 15 Minutes